Quick Answer
DNA X, Inc. reported Stockholders Equity of -$5.70 million for the year ending 2024.
- DNA X, Inc. showed a decrease of -125.5% in Stockholders Equity from 2023 to 2024.
- This data is from DNA X, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$94.94 million | Q2 2018: -$95.03 million | Q3 2018: -$92.83 million | Q1 2019: $4.81 million | Q2 2019: $39.76 million | Q3 2019: $33.31 million | Q1 2020: $15.99 million | Q2 2020: $40.26 million | Q3 2020: $34.34 million | Q1 2021: $19.43 million | Q2 2021: $12.96 million | Q3 2021: $12.65 million | Q1 2022: $11.02 million | Q2 2022: $7.01 million | Q3 2022: $20.67 million | Q1 2023: $20.69 million | Q2 2023: $21.65 million | Q3 2023: $23.11 million | Q4 2023: $22.37 million | Q1 2024: $19.84 million | Q2 2024: $17.47 million | Q3 2024: $15.35 million | Q4 2024: -$5.70 million | Q1 2025: -$1.08 million | Q2 2025: -$1.33 million | Q3 2025: -$701.0 thousand.
- Over the full 8 years of available data (2017 to 2024), DNA X, Inc.'s Stockholders Equity has grown by 93.7%.
- Historical annual values: Fiscal year 2024: -$5.70 million | Fiscal year 2023: $22.37 million | Fiscal year 2022: $20.05 million | Fiscal year 2021: $18.63 million | Fiscal year 2020: $28.41 million | Fiscal year 2019: $25.53 million | Fiscal year 2018: $5.13 million | Fiscal year 2017: -$89.91 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: